

## Executive Branch Personnel

### Public Financial Disclosure Report:

### Periodic Transaction Report (OGE Form 278-T)

#### Filer's Information

---

**Gottlieb, Scott**

Commissioner, Food and Drug Administration, Department of Health & Human Services

---

Electronic Signature - I certify that the statements I have made in this form are true, complete and correct to the best of my knowledge.

/s/ Gottlieb, Scott [electronically signed on 10/05/2017 by Gottlieb, Scott in Integrity.gov]

---

Agency Ethics Official's Opinion - On the basis of information contained in this report, I conclude that the filer is in compliance with applicable laws and regulations (subject to any comments below).

/s/ Hall, Randall, Certifying Official [electronically signed on 10/18/2017 by Hall, Randall in Integrity.gov]

---

Other review conducted by

/s/ Hall, Randall, Ethics Official [electronically signed on 10/18/2017 by Hall, Randall in Integrity.gov]

---

U.S. Office of Government Ethics Certification

/s/ Skalla, Daniel L, Certifying Official [electronically signed on 11/03/2017 by Skalla, Daniel L in Integrity.gov]

---

Data Revised 10/18/2017

---

Comments of Reviewing Officials (public annotations):

PART	#	REFERENCE	COMMENT
N/A	N/A	General	(10/18/2017, Hall, Randall): Filer submitted this report in hard copy on 9/11/2017. The filer was granted a 90 day extension, so the hard copy submission was timely filed. The report has been re-submitted electronically to meet OGE requirements for PAS appointees.

## Transactions

#	DESCRIPTION	TYPE	DATE	NOTIFICATION OVER 30 DAYS AGO	AMOUNT
1	Bright Health	Sale	05/11/17	No	\$15,001 - \$50,000
2	Collective Health	Sale	05/11/17	No	\$15,001 - \$50,000
3	Golden State Medical	Sale	05/11/17	No	\$50,001 - \$100,000
4	Radiology Partners Holdings, LLC	Sale	05/02/17	No	\$100,001 - \$250,000
5	U.S. Renal Care	Sale	05/11/17	No	\$100,001 - \$250,000
6	Angion Biomedica Series A Preferred Stock	Sale	05/11/17	No	\$1,001 - \$15,000
7	Angion Biomedica Warrants	Sale	05/11/17	No	\$1,001 - \$15,000
8	Cell Biotherapy, Inc. Series A	Sale	05/11/17	No	\$15,001 - \$50,000
9	Tivorsan Pharmaceuticals Warrants	Sale	05/11/17	No	\$100,001 - \$250,000
10	Synthesis Energy Warrants	Sale	05/11/17	No	\$15,001 - \$50,000
11	KURE Common Stock	Sale	05/11/17	No	\$1,001 - \$15,000
12	Emmaus Life Sciences Common Stock	Sale	05/11/17	No	\$1,001 - \$15,000
13	Emmaus Life Sciences Warrants	Sale	05/11/17	No	\$1,001 - \$15,000
14	Glytec	Sale	05/10/17	No	\$15,001 - \$50,000
15	Tolero Pharmaceuticals, Inc.	Sale	05/11/17	No	\$100,001 - \$250,000

#	DESCRIPTION		TYPE	DATE	NOTIFICATION OVER 30 DAYS AGO	AMOUNT
16	Lilis Energy Inc Common New		Sale	05/09/17	No	\$50,001 - \$100,000
17	Social Reality Inc Common Class A New	See Endnote	Sale	05/11/17	No	\$50,001 - \$100,000

## Endnotes

PART	#	ENDNOTE
Transactions	17	The information on this electronic form for transactions 1-17 is identical to the information set forth on the hard copy of this form executed and filed September 11.

## Summary of Contents

The 278-T discloses purchases, sales, or exchanges of securities in excess of \$1,000 made on behalf of the filer, the filer's spouse, or dependent child. Transactions are required to be disclosed within 30 days of receiving notification of a transaction but not later than 45 days after the transaction. Filers need not disclose (1) mutual funds and other excepted investment funds; (2) certificates of deposit, savings or checking accounts, and money market accounts; (3) U.S. Treasury bills, notes, and bonds; (4) Thrift Savings Plan accounts; (5) real property; and (6) transactions that are solely by and between the filer, the filer's spouse, and the filer's dependent children.

## Privacy Act Statement

Title I of the Ethics in Government Act of 1978, as amended (the Act), 5 U.S.C. app. § 101 et seq., as amended by the Stop Trading on Congressional Knowledge Act of 2012 (Pub. L. 112-105) (STOCK Act), and 5 C.F.R. Part 2634 of the U. S. Office of Government Ethics regulations require the reporting of this information. The primary use of the information on this report is for review by Government officials to determine compliance with applicable Federal laws and regulations. This report may also be disclosed upon request to any requesting person in accordance with sections 105 and 402(b)(1) of the Act or as otherwise authorized by law. You may inspect applications for public access of your own form upon request. Additional disclosures of the information on this report may be made: (1) to any requesting person, subject to the limitation contained in section 208(d)(1) of title 18, any determination granting an exemption pursuant to sections 208(b)(1) and 208(b)(3) of title 18; (2) to a Federal, State, or local law enforcement agency if the disclosing agency becomes aware of violations or potential violations of law or regulation; (3) to another Federal agency, court or party in a court or Federal administrative proceeding when the Government is a party or in order to comply with a judge-issued subpoena; (4) to a source when necessary to obtain information relevant to a conflict of interest investigation or determination; (5) to the National Archives and Records Administration or the General Services Administration in records management inspections; (6) to the Office of Management and Budget during legislative coordination on private relief legislation; (7) to the Department of Justice or in certain legal proceedings when the disclosing agency, an employee of the disclosing agency, or the United States is a party to litigation or has an interest in the litigation and the use of such records is deemed relevant and necessary to the litigation; (8) to reviewing officials in a new office, department or agency when an employee transfers or is detailed from one covered position to another; (9) to a Member of Congress or a congressional office in response to an inquiry made on behalf of an individual who is the subject of the record; (10) to contractors and other non-Government employees working on a contract, service or assignment for the Federal Government when necessary to accomplish a function related to an OGE

Government-wide system of records; and (11) on the OGE Website and to any person, department or agency, any written ethics agreement filed with OGE by an individual nominated by the President to a position requiring Senate confirmation. See also the OGE/GOVT-1 executive branch-wide Privacy Act system of records.

---